@entity6051 mofetil in combination with interferon beta-1a in the treatment of XXXX : A preliminary study.

@entity1 @entity3780 @entity344 @entity2098 @entity6051
BACKGROUND: The efficacy of @entity6051 mofetil ( @entity2098 ) plus interferon beta-1a (IFNB-1a) in treatment of @entity3780 ( @entity3780 ) was evaluated. METHODS: This was a pilot study with randomized, double-blinded, placebo-controlled design. @entity1 with @entity3780 and Expanded Disability Status Scale score (EDSS) of < 6.0 were included. Those with relapse within the previous two months and prior use of immunomodulatory/immunosuppressive drugs were excluded. @entity1 were randomized into @entity2098 (n = 13) and placebo (n = 13) groups and received weekly intramuscular IFNB-1a plus either @entity2098 or placebo. @entity2098 started by 500 mg/d for one week and weekly escalated by 500 mg/d, until target divided dose of 2000 mg/d and continued for 12 months. Radiologic and clinical assessments were performed at baseline and then at month 12. RESULTS: After one year of therapy, difference between the two groups in number of new T2 lesions was not statistically significant (0.54    0.77 in @entity2098 vs. 1.85    3.2 in placebo group, p = 0.169). Two @entity1 in the placebo group had gadoliniumenhanced lesions and one @entity1 had relapse. There were 3 @entity1 in each group with more than one point progression in EDSS. Common side effect in the @entity2098 group included @entity344 , but no @entity1 discontinued the treatment. CONCLUSIONS: Combination of @entity2098 with IFNB-1a in @entity1 with @entity3780 is well tolerated, but the efficacy of such combination was not statistically significant in this pilot study and deserves further investigation with a larger sample size and a longer follow-up.
